Prostate Cancer Test 'Bounce' No Worry
Temporary Rise and Fall in PSA Levels After Radiation Does Not Affect Survival
WebMD News Archive
Nov. 8, 2006 (Philadelphia) - Men who have a temporary rise on a common
prostate test after radiation therapy for prostate cancer fare as well as those
who don't exhibit the rise, according to the largest, longest study of its
They are no more likely to die in the next 10 years than patients whose
levels do not go up and down, according to the study.
Also, the study found, the prostate cancer is no more likely
to return in men who have the rise in prostate specific antigen (PSA) -- the
so-called PSA bounce -- than in those who do not, says researcher Eric Horwitz,
MD, clinical director of the radiation oncology department at Fox Chase Cancer
Center in Philadelphia.
Horwitz's study looked at more than 7,500 prostate cancer patients treated
Increased levels of PSA, a protein produced by the prostate, may be a sign
of prostate cancer.
But in men who have radiation treatment for prostate cancer, a temporary
rise and fall in PSA levels is common. It affects up to half of patients,
Horwitz tells WebMD the new findings are "a huge deal" for both
doctors and men with prostate cancer. Patients typically become extremely
anxious and may even have unnecessary chemotherapy or hormone treatment if they
have a temporary rise in PSA.
Robert J. Cole, MD, a prostate cancer specialist at the Cancer Center in
Morristown, N.J., who was not involved with the study, agrees.
"This is another nail in the coffin for the PSA bounce," he says.
"We can point to this landmark study and tell patients that 7,532 men were
examined and the PSA bounce did not have any impact on the curability or the
success rate of the treatment. That's pretty impressive."
Horwitz's study was presented at the American Society for Therapeutic
Radiology and Oncology's annual meeting being held in Philadelphia.